会议召开时间：2025 年 04 月 22 日（星期二）17:00-18:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 证券代码：301301 证券简称：川宁生物 公告编号：2025-006 伊犁川宁生物技术股份有限公司 关于举办2024年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 05 月 15 日（星期一）16:00-17:00 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 04 月 22 日 前 访 问 网 址 https://eseb.cn/1nzkfAch7mo或使用微信扫描小程序码进行会前提问，公司将 通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行 回答。 伊犁川宁生物技术股份有限公司（以下简称"公司"）将于 2025 年 4 月 22 日在巨潮资讯网上披露《伊犁川宁生物技术股份有限公司 2024 年年度报告》《伊 犁川宁生物技术股份有限公司 2024 年年度报告摘要》。为便于广大投资者更加 全面深 ...

为满足伊犁川宁生物技术股份有限公司（以下简称"公司"）"双轮驱动" 战略发展需要，进一步拓展公司投资渠道、扩充产业资源和发展优质项目储备， 以提升公司综合竞争力。在不影响公司日常经营和发展、有效控制投资风险的前 提下，公司全资子公司伊犁生合创域企业管理有限公司（以下简称"子公司"） （曾用名：伊犁川宁投资发展有限公司）参与投资上海临港启创生科私募投资基 金合伙企业（有限合伙）（以下简称"合伙企业"），并签署了《上海临港启创 生科私募投资基金合伙企业（有限合伙）有限合伙协议》。合伙企业认缴出资总 额为人民币 56,500 万元，公司作为该合伙企业的有限合伙人（LP）认缴出资人 民币 6,000 万元，占合伙企业认缴出资总额的 10.62%。 具体内容详见公司于 2024 年 9 月 27 日、2025 年 4 月 7 日在巨潮资讯网 （http://www.cninfo.com.cn）上发布的《关于全资子公司参与投资产业基金的公 告》（公告编号：2024-039）、《关于全资子公司参与投资产业基金的进展公告》 （公告编号：2025-004）。 二、投资产业基金的进展情况 近日，子公司收到上海临港启创生科私募投资 ...

Group 1 - The company’s wholly-owned subsidiary, Yili Chuaning Investment Development Co., Ltd., plans to invest RMB 60 million in the Shanghai Lingang Qichuang Biotechnology Private Equity Fund, representing 7.50% of the total committed capital of RMB 800 million [1] - The fund's total committed capital has been reduced from RMB 800 million to RMB 565 million, increasing the company's stake from 7.50% to 10.62% [2] - The changes in the fund's structure are based on the current operational situation and are expected to help maintain stable operations of the fund [2] Group 2 - The fund has not yet completed the registration and filing process with the Asset Management Association of China, indicating some uncertainty in implementation [3] - The company will closely monitor the fund's progress and disclose updates in accordance with relevant regulations [3]

证券代码：301301 证券简称：川宁生物 公告编号：2025-004 伊犁川宁生物技术股份有限公司 关于全资子公司参与投资产业基金的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、投资产业基金的基本情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）全资子公司伊犁生合 创域企业管理有限公司（以下简称"子公司"）（曾用名：伊犁川宁投资发展有 限公司）拟作为有限合伙人（LP）使用自有资金认缴出资人民币 6,000 万元参与 投资上海临港启创生科私募投资基金合伙企业（有限合伙）（曾用名：上海临港 大零号湾启创生科私募投资基金合伙企业（有限合伙））（以下简称"合伙企业"）， 合伙企业目标认缴出资总额为人民币 80,000 万元，公司将占合伙企业认缴出资 总额的 7.50%。具体内容详见公司于 2024 年 9 月 27 日在巨潮资讯网 （http://www.cninfo.com.cn）上发布的《关于全资子公司参与投资产业基金的公 告》（公告编号：2024-039）。 二、投资产业基金的变更情况 近日，公司收到合伙企业工商变更登记通知书，"上海临港大 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The prospects for biomanufacturing are broad, contributing to industrial upgrades. Biomanufacturing, centered on industrial biotechnology, utilizes enzymes and microbial cells in the processing of target products, including bio-based materials, chemicals, and bioenergy. Synthetic biology plays a crucial role as a platform technology in biomanufacturing. The global synthetic biology market is expected to maintain rapid growth, reaching nearly $50 billion by 2028 [3][4][22]. - Technological breakthroughs combined with policy support are driving the synthetic biology industry forward. Factors such as reduced costs of gene synthesis and sequencing, along with advancements in efficient gene editing technologies, provide a solid technical foundation for the rapid development of synthetic biology. Governments worldwide are increasingly prioritizing the development of synthetic biology, with various supportive policies being introduced [4][28]. - Synthetic biology is reshaping industrial models, offering more efficient and environmentally friendly synthesis solutions. It addresses issues associated with traditional chemical synthesis and natural extraction methods, such as high costs, limited yields, and environmental pollution. With breakthroughs in gene editing, enzyme engineering, and metabolic engineering, synthetic biology not only reduces drug production costs but also enhances capacity, enabling large-scale industrial production [4][5]. Summary by Sections Industry Overview - Biomanufacturing is defined as the processing of target products using industrial biotechnology, involving enzymes and microbial cells. Synthetic biology is a key platform technology in this field, enabling the design and construction of biological systems for various applications [13][14]. Policy Support and Technological Breakthroughs - The development of synthetic biology is supported by various policies and technological advancements. Governments are investing in funding, technology, and talent development to foster innovation and industrialization in this field [28][29]. - Major countries are establishing synthetic biology research centers and networks, with the UK and the US leading in policy initiatives to promote synthetic biology [29][30]. Synthetic Biology's Impact on Industrial Models - Synthetic biology is transforming production methods, achieving tasks that traditional biotechnologies cannot, while providing more efficient and eco-friendly synthesis options. This shift is crucial for addressing environmental challenges and enhancing production efficiency [4][5]. Investment Recommendations - Companies to watch include Chuan Ning Biological, Kingfisher Biotech, Kylin Biotech, and Huaxi Biological, which are positioned to benefit from the growth in synthetic biology [5].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The bio-manufacturing sector has vast potential and is poised to drive a new wave of industrial revolution, leveraging industrial biotechnology to produce bio-based materials, chemicals, and bioenergy [3][4] - The global synthetic biology market is expected to maintain rapid growth, projected to approach $50 billion by 2028, with a compound annual growth rate (CAGR) of approximately 24% from 2023 to 2028 [22][24] - Technological breakthroughs and policy support are driving the synthetic biology industry forward, with significant advancements in gene synthesis, sequencing, and editing technologies [4][37] Summary by Sections Industry Overview - Bio-manufacturing utilizes industrial biotechnology, enzymes, and microbial cells, playing a crucial role in producing bio-based materials and chemicals [13] - Synthetic biology is a design-driven science that re-engineers biological systems for useful purposes, with applications across various sectors including healthcare, agriculture, and chemicals [13][22] Policy Support and Technological Breakthroughs - Governments worldwide are increasingly prioritizing synthetic biology, with strategic plans and funding initiatives to support its development [28][29] - The reduction in costs for gene synthesis and sequencing technologies has laid a solid foundation for the rapid advancement of synthetic biology [37] Synthetic Biology Reshaping Industry Models - Synthetic biology is transforming production models, offering more efficient and environmentally friendly synthesis solutions compared to traditional methods [4][22] - The industry is expected to significantly reduce carbon emissions, with estimates suggesting a reduction of 1 to 2.5 billion tons of CO2 annually by 2030 through industrial biotechnology [4] Related Companies - Companies to watch include Chuan Ning Bio, Kingfisher Biotech, and Kailai Ying, which are positioned to benefit from advancements in synthetic biology [5] Investment Recommendations - The report suggests focusing on companies like Chuan Ning Bio, Kingfisher Biotech, and others that are leveraging synthetic biology for growth [5]

证券代码：301301 证券简称：川宁生物 公告编号：2025-003 伊犁川宁生物技术股份有限公司 二、公司在注册有效期内可分期发行超短期融资券，发行完成后，应通过交 易商协会认可的途径披露发行结果。 公司将根据银行间市场情况以及通知书的要求，严格按照《非金融企业债务 融资工具注册发行规则》《非金融企业债务融资工具注册工作规程》《非金融企 业债务融资工具信息披露规则》及有关规则指引规定，结合公司资金需求及市场 情况，在注册额度及有效期内择机发行超短期融资券，并及时履行信息披露义务。 特此公告。 伊犁川宁生物技术股份有限公司董事会 2025 年 2 月 7 日 伊犁川宁生物技术股份有限公司（简称"公司"）分别于 2024 年 4 月 22 日 召开的第二届董事会第五次会议及 2024 年 5 月 13 日召开的 2023 年年度股东大 会审议通过了《关于公司及所属子公司发行非金融企业债务融资工具的议案》， 同意公司及子（分）公司向中国银行间市场交易商协会（简称"交易商协会"） 申请注册发行总额不超过人民币 10 亿元（含）的银行间债券市场非金融企业债 务融资工具，发行品种包括超短期融资券、中期票据等相关监管部 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately 136,000 to 145,000 million yuan for 2024, representing a year-on-year increase of 44.59%[5] - The net profit after deducting non-recurring gains and losses is also projected to be between 136,000 and 145,000 million yuan, reflecting a growth of 45.31% compared to the previous year[5] - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by an accounting firm[11] - The performance forecast period is from January 1, 2024, to December 31, 2024[3] - The board of directors has provided a statement regarding the 2024 performance forecast[12] Factors Influencing Profit - The increase in profit is primarily driven by higher sales and prices of cephalosporin products in 2024[7] - The company has improved its production technology, effectively reducing production costs, which contributed to the increase in net profit[8] - The scale of interest-bearing liabilities has decreased, leading to a reduction in interest expenses compared to the previous year[10] Regulatory Compliance and Disclosure - The company will adhere to relevant laws and regulations for timely information disclosure, urging investors to make cautious decisions[11] - The company emphasizes that the specific financial data for 2024 will be disclosed in the official annual report[11]

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：伊犁川宁生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及《上市公司股东大会规则》等法律、法 规及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"本所"）指 派律师出席了伊犁川宁生物技术股份有限公司（以下简称"公司"）2025 年第一 次临时股东大会（以下简称"本次股东大会"），并对本次股东大会的相关 ...

二〇二四年十二月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东大会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 | 8 | | 第三节 | 股东大会的召集 | 11 | | 第四节 | 股东大会的提案与通知 | 12 | | 第五节 | 股东大会的召开 | 14 | | 第六节 | 股东大会的表决和决议 | 17 | | 第五章 | 董事会 | 22 | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 25 | | 第六章 | 总经理及其他高级管理人员 | 33 | | 第七章 | 监事会 | 35 | | 第一节 | 监事 | 35 | | 第二节 | 监事会 | 35 | | 第八章 | 财务会计制度、利润分配和审计 | 37 | | 第一节 | 财务会计制度 | 37 | | 第二节 | 内部审计 | ...